Celiprolol: Difference between revisions
No edit summary |
No edit summary |
||
| Line 26: | Line 26: | ||
'''Celiprolol''' (brand names Cardem, Selectol, Celipres, Celipro, Celol, Cordiax, Dilanorm) is a [[medication]] in the class of [[beta blocker]]s, used in the treatment of [[hypertension|high blood pressure]]. It has a unique pharmacology: it is a selective [[Beta-1 adrenergic receptor|β1 receptor]] [[receptor antagonist|antagonist]], but a [[Beta-2 adrenergic receptor|β2 receptor]] partial [[agonist]]. It is also a weak [[Alpha-2 adrenergic receptor|α2 receptor]] antagonist. | '''Celiprolol''' (brand names Cardem, Selectol, Celipres, Celipro, Celol, Cordiax, Dilanorm) is a [[medication]] in the class of [[beta blocker]]s, used in the treatment of [[hypertension|high blood pressure]]. It has a unique pharmacology: it is a selective [[Beta-1 adrenergic receptor|β1 receptor]] [[receptor antagonist|antagonist]], but a [[Beta-2 adrenergic receptor|β2 receptor]] partial [[agonist]]. It is also a weak [[Alpha-2 adrenergic receptor|α2 receptor]] antagonist. | ||
A recent clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular [[ | A recent clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular [[Ehlers-Danlos syndrome]]. This study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial rupture in which the layers of the vessel separate prior to complete failure of the artery wall).<ref>{{cite journal | author = Ong K-T et al. | title = Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial | journal = Lancet | year = 2010 | doi=10.1016/S0140-6736(10)60960-9 | volume = 376 | issue = 9751 | pages = 1476–1484 | pmid = 20825986}}</ref> | ||
==References== | ==References== | ||
Revision as of 02:23, 25 July 2014
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C20H33N3O4 |
| Molar mass | 379.49 g/mol |
|
WikiDoc Resources for Celiprolol |
|
Articles |
|---|
|
Most recent articles on Celiprolol |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Celiprolol at Clinical Trials.gov Clinical Trials on Celiprolol at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Celiprolol
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Celiprolol Discussion groups on Celiprolol Patient Handouts on Celiprolol Directions to Hospitals Treating Celiprolol Risk calculators and risk factors for Celiprolol
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Celiprolol |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Celiprolol (brand names Cardem, Selectol, Celipres, Celipro, Celol, Cordiax, Dilanorm) is a medication in the class of beta blockers, used in the treatment of high blood pressure. It has a unique pharmacology: it is a selective β1 receptor antagonist, but a β2 receptor partial agonist. It is also a weak α2 receptor antagonist.
A recent clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers-Danlos syndrome. This study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial rupture in which the layers of the vessel separate prior to complete failure of the artery wall).[1]
References
- ↑ Ong K-T; et al. (2010). "Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial". Lancet. 376 (9751): 1476–1484. doi:10.1016/S0140-6736(10)60960-9. PMID 20825986.
External Links
- Selectol Summary of Product Characteristics (from the IPHA Medicines Compendium)
- Celiprolol data sheet for New Zealand
- Pages with script errors
- CS1 maint: Explicit use of et al.
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Cardiovascular Drugs
- Drug
- Beta blockers
- Antihypertensive agents